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ABSTRACT
Introduction: Local skin responses (LSRs) are
the most common adverse effects of topical
actinic keratosis (AK) therapy. There is currently
no method available that allows objective
characterization of LSRs. Here, the authors
describe a new scale developed to
quantitatively and objectively assess the six
most common LSRs resulting from topical AK
therapy with ingenol mebutate.
Methods: The LSR grading scale was developed
using a 0–4 numerical rating, with clinical
descriptors and representative photographic
images for each rating. Good inter-observer
grading concordance was demonstrated in
peer review during development of the tool.
Data on the use of the scale are described from
four phase III double-blind studies of ingenol
mebutate (n = 1,005).
Results: LSRs peaked on days 4 (face/scalp) or 8
(trunk/extremities), with mean maximum
composite LSR scores of 9.1 and 6.8,
respectively, and a rapid return toward
baseline by day 15 in most cases. Mean
composite LSR score at day 57 was generally
lower than at baseline.
Conclusion: The LSR grading scale is an
objective tool allowing practicing
dermatologists to characterize and compare
LSRs to existing and, potentially, future AK
therapies.
Keywords: Actinic keratosis; Dermatology;
Ingenol mebutate; Local skin response;
Quantitative scale; Severity assessment;
Treatment outcome
INTRODUCTION
Actinic keratosis (AK) is a skin condition caused
by excessive, prolonged exposure to ultraviolet
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light [1]. Topical treatments for AK include
retinoids [2], colchicine [3], and, more
commonly, several formulations of
5-fluorouracil, imiquimod, and diclofenac
sodium 3% gel [4, 5]. Another approach is the
use of ingenol mebutate gel, approved in the
USA [6], European Union [7], Australia, Brazil,
and Canada for the topical treatment of AK in
adults. Each treatment offers specific
advantages and disadvantages as well as
potential complications. The most common
resulting adverse effects (AEs) are local skin
responses (LSRs) at the treatment area,
categorized clinically as erythema, edema,
erosion/ulceration, scabbing/crusting, weeping/
exudates, vesicles/pustules, and flaking/scaling/
dryness.
Historically, LSRs are graded subjectively
(0 = none, 1 = mild, 2 = moderate, and
3 = severe) [5]. During the clinical
development of ingenol mebutate, the Food
and Drug Administration (FDA) indicated that
such subjective grading of LSRs was insufficient
to quantify responses to a topically applied
treatment [8]. It recommended the
development of a quantitative tool for the
assessment of LSRs, incorporating a
photographic scale with numeric grades of
severity, each of which should include clinical
descriptors defining a particular level of
response. The descriptors were to be
sufficiently detailed to minimize inter-observer
variability.
As a consequence, the LSR grading scale was
developed. The scale has since been used in 15
AK studies of ingenol mebutate [9–15], assessing
more than 1,900 cutaneous responses to
treatment from 2006 to 2012 by at least 94
dermatologists [board certified (USA) or with
equivalent certification in country of practice].
Here, the authors describe the development
of the LSR grading scale and present pooled data
from four pivotal phase III studies of
ingenol mebutate [12] to illustrate the
effective use of this scale for the objective
assessment of LSRs.
METHODS
Development of the LSR Grading Scale
A requirement of the scale was that it should
reflect multiple components of possible skin
responses and separate expected skin responses
from AEs that may be considered
complications. Six reactions, namely
erythema, flaking/scaling, crusting, swelling
(edema), vesiculation/pustulation, and erosion/
ulceration, were selected to reflect typical
LSRs seen with topical therapy. Characteristics
of skin responses were identified and allocated a
numeric grade of severity (0–4, with 4 being the
highest grade of severity) based on a concise
written description, with specific parameters,
and accompanied by a visual image of that level
of severity (Fig. 1). No visual image of swelling
was provided because of the difficulties
associated with the effective photographic
representation of different grades of this LSR.
The scores derived from the scale can be used
in two ways. First, the individual LSR category
score represents the type and time course of the
skin response that a topical agent may cause
during and after treatment. Second, the
composite (total) numerical score of the
individual LSRs for each patient provides a
useful tool for analyzing the onset, peak, and
resolution of the range of LSRs in treated
patients. This composite LSR score (0–24)
represents the sum of the scores graded from 0
to 4 on all six individual LSR categories.
The initial version of the scale was tested
using a group of 36 Australian dermatologists
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at the Australian College of Dermatologists
annual meeting, who were asked to grade a
series of photographs of skin responses. These
findings demonstrated good inter-observer
grading concordance. The scale was
subsequently tested by a group of approximately
Fig. 1 Actinic keratosis. The LSR grading scale: a quantitative scale for the evaluation of LSRs arising from topical ingenol
mebutate treatment. LSR Local skin response
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20 dermatologists attending a clinical
investigators’ meeting for ingenol mebutate in
the USA. Good inter-observer concordance was
again reported and minor changes were discussed
and agreed to further enhance the reliability of
the scale.
The final version of the LSR grading scale was
introduced in December 2007 and was used in
the pivotal ingenol mebutate clinical studies. In
all trials, LSR evaluations were conducted by
board-certified dermatologists at all assessment
visits.
Clinical Studies
A total of 1,005 patients were randomized in
two identical phase III, double-blind studies
evaluating the treatment of AKs on the face/
scalp (PEP005-016, NCT00916006; PEP005-025,
NCT00915551) and in another two identical
phase III studies evaluating treatment of
AKs on the trunk/extremities (PEP005-014,
NCT00742391; PEP005-028, NCT00942604)
[12]. Patients in the face/scalp studies (n = 547,
ITT population) applied ingenol mebutate
0.015% QD to a 25-cm2 treatment area for
three consecutive days (n = 277) or vehicle
(n = 270) and those in the trunk/extremities
studies (n = 458) applied ingenol mebutate
0.05% QD to a 25-cm2 treatment area on the
back, back of hand, arm, chest, shoulder or leg
for two consecutive days (n = 226) or vehicle
(n = 232). Composite LSR scores were calculated
at each study visit for each patient [days 1
(baseline pre-treatment), 4, 8, 15, 29, and 57 for
face/scalp; days 1 (baseline pre-treatment), 3, 8,
15, 29, and 57 for trunk/extremities].
Compliance with Ethics Guidelines
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Studies of the Face/Scalp
Figure 2 shows the time course of mean
composite LSR scores for face/scalp treatment
(n = 547) [12]. LSRs were transient and typically
occurred within 1 day of therapy initiation,
peaking in intensity up to 1 week following
completion of treatment. These effects typically
resolved within 2 weeks of therapy. Figure 3
shows representative examples of typical LSR
progression by study visit, with resolution to a
level lower than baseline by day 57. Erythema
and flaking were the most common LSRs, with
vesiculation and erosion occurring less
commonly. Grade 4 vesiculation/erosion was
only seen in 5% of patients.
The mean maximum composite LSR score
over the entire study duration was 9.1 [standard
deviation (SD, 4.1) for ingenol mebutate
0.015% versus 1.8 (SD, 1.6) for vehicle]. When
patients were evaluated by complete clearance
status or partial clearance, there was no
correlation between clearance rate and mean
maximum composite LSR score. In some
patients, clearance was achieved with minimal
composite LSR scores; in other patients
clearance was achieved with no to little
reported LSRs. A maximum composite LSR
score greater than the baseline score was noted
in 97.8% and 35.8% of patients treated with
ingenol mebutate 0.015% and vehicle,
respectively. Most patients (81.8%) treated
with ingenol mebutate 0.015% had their
maximum composite LSR score at day 4 (Fig. 2).
Table 1 shows a summary of composite LSR
scores for face/scalp treatment; Fig. 4 shows the
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distribution of ingenol mebutate-treated
patients who fell within each range of
maximum composite LSR score (0–24). The
majority of patients (81.3%) with face/scalp
lesions had maximum composite LSR scores
between 1 and 12. Only 1.8% of these patients
had composite LSR scores in the most intense
range (19–24). Most patients (99.3%) in the
vehicle group experienced a maximum
composite LSR score between 0 and 12. Table 2
shows maximum LSR scores for the face/scalp
studies.
Studies of the Trunk/Extremities
The time course of the mean composite LSR
score is shown in Fig. 5 for AK treatment on the
trunk/extremities (n = 458, ITT population)
[12]. LSRs were transient and typically
occurred within 1 day of therapy initiation,
peaking in intensity up to 1 week following
treatment completion. These effects typically
resolved within 4 weeks of therapy initiation
[6]. Erythema and flaking were the most
common LSRs; vesiculation and erosion
occurred less commonly. Grade 4 vesiculation/
erosion was only seen in 1% of patients.
The mean maximum composite LSR score for
patients given ingenol mebutate 0.05% was 6.8
(SD, 3.5) compared with 1.6 (SD, 1.5) for
patients given vehicle. The maximum
composite LSR score was higher than the
baseline LSR score in 96.4% of patients
receiving ingenol mebutate 0.05% and 31.0%
of patients receiving vehicle. The maximum
composite LSR score for patients treated with
ingenol mebutate 0.05% occurred on day 3 for
55.1%, on day 8 for 32.4%, and on day 15 for
Fig. 2 Actinic keratosis. Time course of mean composite LSR scores in phase III face/scalp studies of patients treated with
ingenol mebutate 0.015%. LSR Local skin response
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8.4% of patients. No patient experienced a
maximum composite LSR score at day 29,
although one (0.4%) had a maximum
composite LSR score at day 57. This patient’s
aberrant pattern of increasing LSR scores in the
treatment area on the leg over the observation
period may have been due to psoriasis, a pre-
existing condition found in the treatment area
by a post-study biopsy. No other abnormalities
that might have accounted for this anomaly
were reported in this patient.
Table 1 shows a summary of composite LSR
scores for trunk/extremities locations; Fig. 4
shows the distribution of ingenol mebutate-
Fig. 3 Actinic keratosis. Patient photographs with varying composite LSR scores (range 1–24) for treatment on face/scalp
are shown per visit from day 1 (baseline) to day 57. LSR Local skin response
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treated patients who fell within each range
of maximum composite LSR score (0–24).
The majority of patients (93.3%) with trunk/
extremity lesions treated with ingenol mebutate
experienced a maximum composite LSR score
between 1 and 12. No patient in the study had
composite LSR scores that exceeded 18. Most
patients (98.7%) in the vehicle group
experienced a maximum composite LSR score
of 0–6. Table 2 lists the maximum LSR scores in
the trunk/extremities studies. Patient
photographs with varying composite LSR
scores (range 1–18) for treatment on trunk/
extremities are shown per visit from day 1
(baseline) to day 57 (Fig. 6).
DISCUSSION
LSRs are a common feature of the numerous
ablative and non-ablative approaches to treat
AK. These have generally been characterized as
Table 1 Summary of composite LSR scores in phase III studies (safety population)











Baseline score, mean (SD) 1.4 (1.5) 1.1 (1.2) 1.0 (1.2) 1.1 (1.3)
Maximum score post-baseline,
mean (SD)a
9.1 (4.1) 1.8 (1.6) 6.8 (3.5) 1.6 (1.5)
Patients with a score[0,
n (%)
272 (99.3) 199 (73.4) 223 (99.1) 158 (68.1)
Patients with a
score[baseline, n (%)
268 (97.8) 97 (35.8) 217 (96.4) 72 (31.0)
Study day of maximum score, n (%)
Number of scores[baselineb 5 (1.8) 174 (64.2) 8 (3.6) 160 (69.0)
Day 3/4 224 (81.8) 34 (12.5) 124 (55.1) 32 (13.8)
Day 8 39 (14.2) 22 (8.1) 73 (32.4) 19 (8.2)
Day 15 4 (1.5) 18 (6.6) 19 (8.4) 11 (4.7)
Day 29 0 (0.0) 17 (6.3) 0 (0.0) 9 (3.9)
Day 57 1 (0.4) 6 (2.2) 1 (0.4) 1 (0.4)
LSR local skin response, SD standard deviation
a The maximum composite LSR score is independent of time; it reﬂects the highest score at any time post-baseline
b All composite LSR scores post-baseline are below the baseline composite LSR score
Fig. 4 Actinic keratosis. Distribution of maximum com-
posite LSR scores in phase III studies (safety population).
LSR Local skin response
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Table 2 Summary of the maximum score for each of the six individual LSRs post-baseline in phase III studies (safety
population)
Maximum grade post-baseline Face/scalp Trunk/extremities
Ingenol mebutate








0 1 (0.4) 105 (38.7) 5 (2.2) 112 (48.3)
1 25 (9.1) 127 (46.9) 31 (13.8) 102 (44.0)
2 56 (20.4) 33 (12.2) 94 (41.8) 16 (6.9)
3 125 (45.6) 6 (2.2) 61 (27.1) 2 (0.9)
4 66 (24.1) 0 (0.0) 34 (15.1) 0 (0.0)
Any grade[0 272 (99.3) 166 (61.3) 220 (97.8) 120 (51.7)
Flaking/scaling, n (%)
0 7 (2.6) 89 (32.8) 3 (1.3) 83 (35.8)
1 52 (19.0) 142 (52.4) 52 (23.1) 131 (56.5)
2 91 (33.2) 36 (13.3) 86 (38.2) 15 (6.5)
3 98 (35.8) 4 (1.5) 66 (29.3) 3 (1.3)
4 25 (9.1) 0 (0.0) 18 (8.0) 0 (0.0)
Any grade[0 266 (97.1) 182 (67.2) 222 (98.7) 149 (64.2)
Crusting, n (%)
0 44 (16.1) 219 (80.8) 50 (22.2) 188 (81.0)
1 85 (31.0) 47 (17.3) 105 (46.7) 38 (16.4)
2 64 (23.4) 5 (1.8) 39 (17.3) 4 (1.7)
3 64 (23.4) 0 (0.0) 23 (10.2) 2 (0.9)
4 16 (5.8) 0 (0.0) 8 (3.6) 0 (0.0)
Any grade[0 229 (83.6) 52 (19.2) 175 (77.8) 44 (19.0)
Swelling, n (%)
0 56 (20.4) 257 (94.8) 82 (36.4) 219 (94.4)
1 88 (32.1) 12 (4.4) 65 (28.9) 13 (5.6)
2 67 (24.5) 2 (0.7) 51 (22.7) 0 (0.0)
3 48 (17.5) 0 (0.0) 20 (8.9) 0 (0.0)
4 14 (5.1) 0 (0.0) 7 (3.1) 0 (0.0)
Any grade[0 217 (79.2) 14 (5.2) 143 (63.6) 13 (5.6)
Vesiculation/pustulation, n (%)
0 119 (43.4) 270 (99.6) 127 (56.4) 230 (99.1)
1 36 (13.1) 1 (0.4) 46 (20.4) 1 (0.4)
2 53 (19.3) 0 (0.0) 30 (13.3) 1 (0.4)
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Fig. 5 Actinic keratosis. Time course of mean composite LSR scores in phase III trunk/extremities studies of patients
treated with ingenol mebutate 0.05%. LSR Local skin response
Table 2 continued
Maximum grade post-baseline Face/scalp Trunk/extremities
Ingenol mebutate







3 50 (18.2) 0 (0.0) 19 (8.4) 0 (0.0)
4 15 (5.5) 0 (0.0) 3 (1.3) 0 (0.0)
Any grade[0 154 (56.2) 1 (0.4) 98 (43.6) 2 (0.9)
Erosion/ulceration, n (%)
0 186 (67.9) 267 (98.5) 167 (74.2) 226 (97.4)
1 55 (20.1) 4 (1.5) 37 (16.4) 6 (2.6)
2 26 (9.5) 0 (0.0) 15 (6.7) 0 (0.0)
3 5 (1.8) 0 (0.0) 4 (1.8) 0 (0.0)
4 1 (0.4) 0 (0.0) 2 (0.9) 0 (0.0)
Any grade[0 87 (31.8) 4 (1.5) 58 (25.8) 6 (2.6)
LSR Local skin response
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Fig. 6 Actinic keratosis. Patient photographs with varying composite LSR scores (range 1–18) for treatment on trunk/
extremities are shown per visit from day 1 (baseline) to day 57. LSR Local skin response
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mild, moderate, or severe, usually at the
discretion of the investigator [5]. The LSR
grading scale described here provides an
objective and quantitative method for
characterizing LSRs in patients receiving
treatment with ingenol mebutate. The scale
was shown to be associated with good inter-
observer grading concordance in peer review
assessments.
In clinical studies of ingenol mebutate in AK,
including the four phase III studies discussed
here [12] and several phase I and II studies [9,
11, 16, 17], the scale effectively recorded the
onset, maximum severity, and subsequent
return to baseline for each one of six
treatment-related responses and generated an
overall composite score, taking all potential
types of LSR into consideration. In the four
phase III studies, the scale demonstrated that
LSRs associated with ingenol mebutate during
treatment for AK were transient, were detectable
within 1 day of treatment initiation and peaked
in intensity within the first week following
completion of treatment. These effects
generally resolved within 2 weeks of treatment
initiation for areas on the face and scalp and
within 4 weeks of treatment initiation for areas
on the trunk and extremities; while exhibiting a
longer peak than on the face and scalp, LSRs on
the trunk and extremities were of a lower
intensity [6, 12]. There was good
reproducibility between the individual phase
III studies. The tabular and graphic
representations of LSR data presented here
illustrate the ease with which rapid
comparison of individual LSRs can be made
and translated into a meaningful dialog with
candidate patients for topical field therapy.
More recently, the scale has been successfully
used to assess LSRs in a first-in-man study of
LEO43204 for topical treatment of AK on the
forearms [18] and has also been used during
treatment with ingenol mebutate for superficial
basal cell carcinomas [19, 20].
Previous AK studies have not uniformly
reported objectively the incidence, frequency,
severity, or time course of LSRs, making
comparison of the tolerability of different
treatment modalities and dosing regimens
difficult. This highlights the need for a
standardized method of LSR assessment. To
date, the LSR grading scale has not been used
to assess LSRs with drugs other than ingenol
mebutate and this is an area that merits
investigation. It should be noted that the
timing of LSR evaluations would need to be
individualized based on the particular
compounds under investigation because the
time course of reactions differs for products
with different treatment courses.
CONCLUSION
The objective, quantitative LSR grading scale
described here provides clinicians with a
valuable assessment tool. The ability to rate
individual LSR categories (erythema, flaking/
scaling, crusting, swelling, vesiculation/
pustulation, and erosion/ulceration) and to
generate a composite objective LSR score will
enable dermatologists to compare the
tolerability of current and future therapeutic
modalities for AK in clinical trials and,
potentially, real-world practice settings.
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